Varian expands HDR (high dose rate) brachytherapy with MDS deal
This article was originally published in Clinica
Varian Medical Systems is to buy MDS Nordion's high dose rate (HDR) brachytherapy business for around $11m in cash. When combined with its own products, the deal will give Varian the broadest range of delivery systems and applicators for HDR brachytherapy, Palo Alto, California-based Varian says. It will also boost its presence in international markets, especially Europe.
You may also be interested in...
Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.
Paracetamol, acetylcysteine and loperamide among list of OTC drugs deemed "essential" by Spain in the fight against coronavirus.
Mylan, in partnership with Indian firm Lupin, will be looking to rival Biogen and Sandoz by introducing an etanercept biosimilar in European markets following a positive opinion by the EMA’s CHMP on Mylan's application.